摘要
目的:通过血清中白介素-17(IL-17)、胰岛素样生长因子-1(IGF-1)和可溶性细胞间粘附分子-1(ICAM-1)的水平表达及其相关性,对经^(131)I治疗的甲亢伴有甲状腺相关眼病患者的眼眶活动性进行评价。方法:88例Graves眼病(GO)患者依据临床活动性评分(CAS)标准分为GO活动期组(活动期组)52例、GO静止期组(静止期组)36例,另设Graves病无眼病组(无眼病组)34例和健康对照组(对照组)26例。采用酶联免疫吸附法测定血清IL-17、IGF-1、ICAM-1水平,同时测定血清游离三碘甲状原氨酸(FT_3)、游离甲状腺素(FT_4)、超敏促甲状腺素(sTSH)、促甲状腺素受体抗体(TRAb)水平。结果:经^(131)I治疗后,GO活动期组患者血清IL-17、IGF-1、ICAM-1水平明显高于健康对照组、静止期组和无眼病组(P<0.01);静止期组的血清IL-17水平高于健康对照组和无眼病组(P<0.05)。无眼病组的血清IL-17、IGF-1和ICAM-1水平与健康对照组比较,均无统计学差异(P> 0.05)。患者血清IL-17与ICAM-1、IGF-1的相关性分别为r=0.847、r=0.806(P<0.01);IGF-1与ICAM-1的相关性分别为r=0.882(P<0.01)。结论:Graves眼病患者经^(131)I治疗后血清IL-17、IGF-1、ICAM-1的表达水平明显高于静止期组。无眼病组及健康对照组,三个指标具有良好的相关性,对于GO眼病的病变进展监测和治疗效果观察具有一定的指导意义。
Objective: The expression of serum interleukin-17(IL-17), insulin-like growth factors-1(IGF-1) and intercellular adhesion molecule-1(ICAM-1) are used to evaluate the intraorbital inflammatory activity of hyperthyroidism with thyroid associated ophthalmopathy patients treated by 131I. Methods: 88 patients with Graves’ ophthalmopathy(GO) involved in this study were divided into 2 groups according to the clinical activity score(CAS): active GO group(n=52) and resting GO group(n=36). 34 no ophthalmopathy GD and 26 healthy subjects groups were served as control separately. The levels of serum IL-17, IGF-1 and ICAM-1 were determined by ELISA, and the levels of serum FT3, FT4, sTSH and TRAb were detected. Results: After 131I treatment, serum IL-17, IGF-1 and ICAM-1 levels of active GO group were significantly higher than those of all other groups(P<0.01);and serum IL-17 level of resting GO group was higher than the healthy control and no ophthalmopathy GD groups(P<0.05). The serum levels of IL-17, IGF-1 and ICAM-1 were not statistically significant(P> 0.05) in no ophthalmopathy GD groups compared with healthy control group. Serum IL-17 has correlation with ICAM-1 and IGF-1, and the correlation coefficient(r) was 0.847 and 0.806(P<0.01), separately. The value of r between ICAM-1 and IGF-1 is 0.882(P<0.01). Conclusion: After 131I treatment, serum IL-17, IGF-1 and ICAM-1 levels of active GO group were significantly higher than those in all other groups(P<0.01). The three indicators exhibited a good correlation, which can be used to monitor the disease progress and therapeutic effect of patient with Graves’ ophthalmopathy.
作者
张立颖
褚俏梅
李方都
ZHANG Liying;CHU Qiaomei;LI Fangdu(Department of Nuclear Medicine,Liqun Hospital,Putuo District,Shanghai,Shanghai 200333)
出处
《陕西医学杂志》
CAS
2019年第3期393-396,共4页
Shaanxi Medical Journal
基金
上海市卫生和计划生育委员会科研课题(20134304)
